Quality of life and health utility index in type 2 diabetes mellitus patients with various forms of hypoglycemia receiving basal-bolus insulin therapy

Analysis of the results of observational program «Quality of life, symptoms of hypoglycemia and treatment satisfaction in patients with type 2 diabetes receiving basal-bolus insulin therapy» are presented. One thousand patients with type 2 diabetes mellitus (DM2) from ten regions of Russia were included in the above program. The quality of life of DM2 patients with different forms of hypoglycemia on insulin therapy and their distribution according to the grades of quality of life impairment were studied; the health utility index ( Ut) for various forms of hypoglycemia was determined. Quality of life in DM2 patients with hypoglycemia was lower than in those without hypoglycemia. Patients with severe and nocturnal hypoglycemia episodes recorded the expressed disturbances in quality of life; the majority of patients in this group had critical or severe quality of life impairment. On the basis of real-world practice data, the values of health utility index for patients with and without hypoglycemia were determined. The obtained values of health utility index can be used to calculate QALY in pharmacoeconomic analysis.

сахарный диабет второго типа, гипогликемия, качество жизни больных, индекс полезности для здоровья, наблюдательное исследование, обсервационное исследование, EQ-5D, SF-6D, HUI, QALY, type 2 diabetes mellitus, hypoglycemia, quality of life, health utility index, observational study, EQ-5D, SF-6D, HUI, QALY

1. Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care. 2012; 35(6): 1364-1379.

2. Дедов И.И., Шестакова М.В. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации). Сахарный диабет. 2010; 5: 9-16.

3. Колбин А.С. Фармакоэкономика базально-болюсной инсулинотерапии сахарного диабета 2 типа. Практическая фармакоэкономика. Эндокринология (научный сборник) Под ред. Р.У Хабриева. 2011, ООО Издательство «Р-Врач»: 67-75.

4. Майоров А.Ю., Мельникова О.Г. Клинические и психологические аспекты гипогликемии при сахарном диабете. Сахарный диабет. 2010;(3):46-50.

5. Davis R.E., Morrissey M., Peters J.R. et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005; 21(9):1477-1483.

6. Henderson J.N., Allen K.V., Deary I.J. et al. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med.2003;20(12):1016-1021.

7. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине (3-еизд., перераб. идополненное), под ред. академика РАМНЮ.Л. Шевченко. М.: РАЕН, 2012.

8. Ягудина Р.И., Куликов А.Ю., Литвиненко М.М. QALY: история, методология и будущее метода. Фармакоэкономика. 2010; 3 (1): 7-11.

9. Methods for the Analysis of Costs and Cost-Effectiveness in Randomized Studies [Электронный ресурс]. URL: http://www.ispor.org/OpenSourceIndex/ cached/www.uphs.upenn.edu/dgimhsr/costgrnt.PDF (дата обращения: 01.06.2012).

10. National Institute for Health and Clinical Excellence. Available from: www.nice.org.uk. [Accessed March 7, 2010]

11. Dawson D., Gravelle H., O’Mahony M., et al. Developing new approaches to measuring NHS outputs and productivity. Summary report// CHE Research Paper 6. York, UK: Center for Health Economics, The University of York.

12. Weinstein M.C., Torrance G., McGuire A., et al. QALY: Thebasics.ValueinHealth. 2009;12: 5-9.

13. Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9: 142-149.

14. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med. 2008; 148: 956-961.

15. Erik Nord. The Person Trade-Off Approach to Valuing Health Care Programs, 1994.

16. Kaplan, Robert M. Utility assessment for estimating quality-adjusted life years. Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. 1995; 31-60. Retrieved 2014-05-06.

17. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd. ed. Ottawa: The Agency; 2006.Available:>http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf<< (accessed 2007 Feb 9).

18. Sullivan P. W., Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006; 26(4): 410-420.

19. Fanshel S., Bush J.W. A health status index and its application to health service outcomes. Oper Res. 1970;18;1021-1066.

20. Brazier J., Usherwood T., Harper R., Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J ClinEpidemiol. 1998, 58: 1115-28.

21. Новик А.А., Ионова Т.И., Гандек Б. и др. Показатели качества жизни населения Санкт-Петербурга. Пробл. стандартизации в здравоохр. 2001. № 4: 22-31.

22. Clarke P., Gray A., Holman R. Estimating utility values for health states of type 2 diabetic patients using theEQ-5D (UKPDS 62). Med Decis Making. 2002; 22(4): 340-349.

23. Colquitt J.L., Green C., Sidhu M.K. et al. Clinical and cost effectiveness of continuous subcutaneous insulin infusion for diabetes. London (UK): National Institute of Clinical Excellence (NICE); 2002. Available: >>http://www.nice.org.uk/download.aspx?o=38421<< (accessed 2006 Sep 19).

24. Colquitt J.L., Green C., Sidhu M.K. et al. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess (Winch Eng) 2004; 8(43).

25. Sullivan P.W., Lawrence W.F., Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care.2005; 43(7): 736-749.

26. Brazier J., Roberts J., Deverill M. The estimation of a preference-based measure of health from the SF-36.J Health Econ. 2002, 21: 271-292.

27. Brazier J.E., Roberts J. The estimation of a preference-based measure of health from the SF-12.Med Care2004, 42: 851-859.

28. Ferreira L.N., Ferreira P.L., Pereira L.N., Brazier J. An application of the SF-6D to create health values in Portuguese working age adults. J of Med Economics 2008, 11: 215-233.

29. Cruz L.N., Camey S.A., Hoffman J.F., Rowen D. Estimating the SF-6D value set for a population-based sample of Brazilians. Value in Health. 2011, 14: 108-114.